Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.62 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.62 |
| ▸ | PREP | P48147 | 3/20 | 0.61 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14453057 | 0.96 | FKBP1A (0.61) | KLK7KLK5PREPCTRB1NPSR1 | |
| SCHEMBL16272917 | 0.91 | FKBP1A (0.66) | KLK7KLK5PREPCTRB1NPSR1 | |
| SCHEMBL7326760 | 0.91 | FKBP1A (0.66) | KLK7KLK5PREPCTRB1NPSR1 | |
| SCHEMBL5525089 | 0.87 | PREP (0.67) | KLK7KLK5PREPCTRB1NPSR1 | |
| SCHEMBL4724457 | 0.87 | PREP (0.67) | KLK7KLK5PREPCTRB1NPSR1 | |
| SCHEMBL8747162 | 0.87 | KLK7 (0.62) | KLK7KLK5PREPCTRB1NPSR1 | |
| SCHEMBL630112 | 0.87 | PREP (0.67) | KLK7KLK5PREPCTRB1NPSR1 | |
| SCHEMBL8747160 | 0.87 | KLK7 (0.62) | KLK7KLK5PREPCTRB1NPSR1 | |
| SCHEMBL20519 | 0.87 | PREP (0.64) | KLK7KLK5PREPCTRB1NPSR1 | |
| SCHEMBL205438 | 0.87 | PREP (0.64) | KLK7KLK5PREPCTRB1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143249-B2 | Prodrugs of A2B adenosine receptor antagonists | GILEAD SCIENCES, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110160162-A1 | PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS | GILEAD SCIENCES, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| EP-2301937-A1 | Prodrugs of A2b adenosine receptor antagonists | CV THERAPEUTICS, INC. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20100056538-A1 | Pro-drugs of A2B Adenosine Receptor Antagonists | GILEAD PALO ALTO, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-7625881-B2 | Prodrugs of A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-20060293283-A1 | Prodrugs of A2B adenosine receptor antagonists | GILEAD PALO ALTO, INC. | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160162-A1 | PRODRUGS OF A2B ADENOSINE RECEPTOR ANTAGONISTS | ADORA2B, ADORA2A, ADORA1 | KLK7 4172/4885KLK5 4480/4885PREP 734/4885 |
| US-20100056538-A1 | Pro-drugs of A2B Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA1 | KLK7 4488/4885KLK5 4442/4885PREP 191/4885 |
| US-20060293283-A1 | Prodrugs of A2B adenosine receptor antagonists | ADORA2B, ADORA2A, ADORA1 | KLK7 4172/4885KLK5 4480/4885PREP 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.